Drug review fees in Europe to increase

03/11/2013 | In-PharmaTechnologist.com

The European Medicines Agency anticipates that fees for drug reviews will increase approximately 2.6% beginning in April, primarily to account for inflation. The EMA has also announced that it will reduce the current 75% fee reduction it offers for production of orphan drugs and use part of the additional revenue to fund salary and benefit increases.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN